By jurisdiction
Sport / anti-doping (WADA)
Every compound we track that has a recorded status under Sport / anti-doping (WADA). Tap a name for the full picture, including the U.S. status and primary sources.
| Compound | Status here | Note |
|---|---|---|
| AOD-9604 | Restricted | Named in S2.2.3 of the 2027 Prohibited List as a growth hormone fragment (“e.g. AOD-9604 and hGH 176-191”); prohibited at all times. |
| BPC-157 | Restricted | Prohibited at all times under category S0 (non-approved substances). Unchanged on the 2027 List (published Sep 21, 2026; in force Jan 1, 2027). |
| Cagrilintide | Restricted | Prohibited at all times, but not listed by name - captured by the S0 catch-all for substances with no regulatory approval for human use. |
| CJC-1295 | Restricted | Prohibited at all times under S2 as a growth-hormone-releasing factor analogue. |
| Dihexa | Restricted | Not individually named, but prohibited at all times under the S0 catch-all for non-approved substances (2027 List). |
| Emideltide (DSIP) | Restricted | Not individually named, but prohibited at all times under the S0 catch-all for non-approved substances. |
| Epitalon | Restricted | Not individually named, but prohibited at all times under the S0 catch-all for non-approved substances. |
| Ipamorelin | Restricted | Prohibited at all times under S2 as a growth-hormone secretagogue. |
| Kisspeptin-10 | Restricted | Named in S2.2.1: “kisspeptin and its agonist analogues” are testosterone-stimulating peptides prohibited at all times in males (2026 and 2027 Lists). |
| KPV | Restricted | Not individually named, but prohibited at all times under the S0 catch-all for non-approved substances. |
| LL-37 (cathelicidin) | Restricted | Not individually named, but prohibited at all times under the S0 catch-all for non-approved substances (2027 List). |
| Melanotan II | Restricted | Prohibited at all times, but not listed by name - captured by the S0 catch-all for non-approved substances (also argued under S2). |
| MOTS-c | Restricted | Explicitly named on the 2026 Prohibited List under S4.4.1 (metabolic modulators / AMPK activators); prohibited at all times. Still listed on the 2027 List (published Sep 21, 2026; in force Jan 1, 2027). |
| Retatrutide | Restricted | Prohibited at all times, but not listed by name - captured by the S0 catch-all for substances with no regulatory approval for human use. |
| Selank | Restricted | Falls under S0 (non-approved substances); prohibited at all times for tested athletes. |
| Semax | Restricted | Not individually named, but prohibited at all times under the S0 catch-all for non-approved substances. |
| Sermorelin | Restricted | Named in S2.2.4 (GHRH and its analogues) on the 2026 and 2027 Prohibited Lists; prohibited at all times. |
| TB-500 (Thymosin Beta-4) | Restricted | Prohibited at all times as a growth factor / non-approved substance. Unchanged on the 2027 List (published Sep 21, 2026; in force Jan 1, 2027). |
| Tesamorelin | Restricted | Named in S2.2.4 (GHRH and its analogues) on the 2026 and 2027 Prohibited Lists; prohibited at all times. |
| GHK-Cu | Unscheduled | Not explicitly named on the Prohibited List. |
| NAD+ | Unscheduled | Not named on the Prohibited List, but IV infusions over 100 mL per 12 hours are prohibited as a method (M2.2). |
| PT-141 (bremelanotide) | Unscheduled | Not named on the 2026 or 2027 Prohibited List or the 2027 Monitoring Program; S0 covers only substances with no government approval for human use, and bremelanotide is FDA-approved. |
| Semaglutide (compounded) | Unscheduled | Not prohibited; on the WADA Monitoring Program since 2024. WADA confirmed GLP-1 status is unchanged for 2027 (Sep 21, 2026). |
| SS-31 (elamipretide) | Unscheduled | Not named on the 2027 Prohibited List. S0 covers only substances with no current government approval for human therapeutic use, and elamipretide has been FDA-approved since Sep 2025. |
| Thymosin Alpha-1 | Unscheduled | Not specifically named on the Prohibited List (distinct from thymosin beta-4, which is prohibited). |
| Tirzepatide (compounded) | Unscheduled | Not prohibited; added to the WADA Monitoring Program effective Jan 1, 2026. WADA confirmed GLP-1 status is unchanged for 2027 (Sep 21, 2026). |